Abbott Laboratories Common Stock (ABT)
Stock · NYSE · Health Care
$104.88as of 10/16/2026
Price chart
Active signals
ABT Signal Track Record
How signals performed across all stocks →What ABT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 29 | +1.2% | 52% | September 8, 2026 |
| Bollinger Band Breakout | 25 | -1.8% | 44% | August 21, 2026 |
| Bollinger Band Breakdown | 21 | -1.2% | 43% | October 1, 2026 |
| 200-Day Moving Average TouchActive now | 20 | -0.8% | 45% | September 22, 2026 |
| Any 20-session window (baseline) | -0.1% | 50% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic chol…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 122,000
- Website
- www.abbott.com
Fundamentals
- 1-day range
- $104.2$105.88
- Market cap
- $186.81B
- P/E (trailing)
- 33.41
- P/E (forward)
- 17.29
- EPS (trailing)
- $3.11
- Dividend yield
- 1.98%
- Beta
- 0.55
- Avg. volume
- 8.91M
- Ex-dividend date
- October 15, 2026
- Dividend pay date
- November 16, 2026
How Abbott Laboratories Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 20, 2026 · via SEC EDGAR / Finnhub
Forecasts
26 analyst ratings
Abbott Laboratories Common Stock Competitors
Chosen by industry and closest market cap.
- ABTAbbott Laboratories Common Stock$104.89▲ 0.20%Market cap $186.81BP/E 33.41$81.97$132.03
- NVONovo Nordisk A/S Common Stock$38.83▼ 0.99%Market cap $203.55BP/E 9.74$224.25$409.95
- PFEPfizer Inc. Common Stock$29.58▲ 0.48%Market cap $149.33BP/E 39.08$23.62$29.49
- BMYBristol-Myers Squibb Company Common Stock$59.75▼ 1.35%Market cap $131.04BP/E 13.53$42.52$68.64
- AZNAstraZeneca PLC Ordinary Shares$165.41▼ 0.76%Market cap $249.78BP/E 24.19$11,404$15,730
- VRTXVertex Pharmaceuticals Incorporated Common Stock$499.74▼ 1.77%Market cap $122.68BP/E 29.32$403.16$560.25
- GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)$49.51▲ 1.00%Market cap $105.65BP/E 15.09$1,592$2,282
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ABT Abbott Laboratories Common Stock | $186.81B | 33.41 | $104.89 | ▲ 0.20% | $81.97$132.03 |
| NVO Novo Nordisk A/S Common Stock | $203.55B | 9.74 | $38.83 | ▼ 0.99% | $224.25$409.95 |
| PFE Pfizer Inc. Common Stock | $149.33B | 39.08 | $29.58 | ▲ 0.48% | $23.62$29.49 |
| BMY Bristol-Myers Squibb Company Common Stock | $131.04B | 13.53 | $59.75 | ▼ 1.35% | $42.52$68.64 |
| AZN AstraZeneca PLC Ordinary Shares | $249.78B | 24.19 | $165.41 | ▼ 0.76% | $11,404$15,730 |
| VRTX Vertex Pharmaceuticals Incorporated Common Stock | $122.68B | 29.32 | $499.74 | ▼ 1.77% | $403.16$560.25 |
| GSK GSK plc American Depositary Shares (Each representing two Ordinary Shares) | $105.65B | 15.09 | $49.51 | ▲ 1.00% | $1,592$2,282 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- History Says Abbott Stock Could More Than Double by 2036. Here’s Why I Just Added It to My Portfolio.Yahoo · 10/10/2026
- Banking Bellwethers Kick Off Earnings, Fed Chair's Speech In FocusSeekingAlpha · 10/10/2026
- Abbott (ABT) Stock Could Be 24% Overvalued After Heart Failure NewsYahoo · 10/10/2026
- Dividend Champion, Contender, And Challenger Highlights: Week October 11SeekingAlpha · 10/9/2026
- Cancer Stocks to Consider as Oncology Innovation AcceleratesYahoo · 10/9/2026
- Is it the Right Time to Hold TNDM Stock in Your Portfolio?Yahoo · 10/9/2026
- Market Chatter: Trump Disclosed 517 Securities Transactions in August, Including Up to $25 Million Meta PurchaseYahoo · 10/8/2026
- Is it the Right Time to Add Phibro Stock to Your Portfolio?Yahoo · 10/8/2026
- This Hewlett Packard Enterprise Analyst Turns Bullish; Here Are Top 5 Upgrades For Fridaybenzinga · 10/2/2026
Insider Activity
Insider Actions →- Nita Ahuja · September 30, 2026 · Grant318 @ $98.83
- Michael F. Roman · September 30, 2026 · Grant381 @ $98.83
- John G. Stratton · September 30, 2026 · Grant397 @ $98.83
- Kevin T. Conroy · September 30, 2026 · Grant318 @ $98.83
- Patricia Paola Gonzalez · September 30, 2026 · Grant333 @ $98.83
- Kevin T. Conroy · September 23, 2026 · Tax Withholding52.5K @ $103.99
- John A. McCoy Jr. · September 2, 2026 · Sale27 @ $109.54
- Philip P. Boudreau · September 1, 2026 · Tax Withholding388 @ $110.36
- John A. McCoy Jr. · September 1, 2026 · Tax Withholding52 @ $110.36
- Robert B. Ford · August 25, 2026 · Option Exercise247.0K @ $59.94
- Robert B. Ford · August 25, 2026 · Option Exercise151.9K @ $44.4
- Robert B. Ford · August 25, 2026 · Sale180.3K @ $116.19
- Robert B. Ford · August 25, 2026 · Sale218.5K @ $115.57
- Louis H. Morrone · August 12, 2026 · I12 @ $107.99
- Louis H. Morrone · August 11, 2026 · Sale5.8K @ $109.83
Institutional Ownership
March 31, 2026
- Total shares held
- 1.30B
- Total value held
- $128.42B
- Institutional holders
- 3061
- Unknown145.79M
- Unknown112.95M
- Unknown79.58M
- Unknown49.78M
- Unknown45.50M
- Unknown39.15M
- Unknown37.50M
- Unknown30.10M
- Unknown27.07M
- Unknown20.02M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Abbott Labs launches Ensure Max Protein as earnings preview approaches
Abbott Laboratories introduced a new high‑protein nutritional drink, Ensure Max Protein, expanding its consumer health lineup. At the same time, investors are looking ahead to the company's third‑quarter earnings, with analysts focusing on revenue and earnings per share estimates. TD Cowen reaffirmed its positive view of Abbott, keeping a $135 price target, which aligns with the analyst consensus range. The stock is currently near a long‑standing support level around $99.90.
Abbott Labs launches Ensure Max Protein as earnings preview approaches. Abbott Laboratories introduced a new high‑protein nutritional drink, Ensure Max Protein, expanding its consumer health lineup. At the same time, investors are looking ahead to the company's third‑quarter earnings, with analysts focusing on revenue and earnings per share estimates. TD Cowen reaffirmed its positive view of Abbott, keeping a $135 price target, which aligns with the analyst consensus range. The stock is currently near a long‑standing support level around $99.90.